Cilostazol for Prevention of Recurrent Stroke Trial

Part of paid clinical trials in Stanford, California.

Sponsor
Stanford University
Study ID
NCT07174414
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Ischemic Stroke
  • Myocardial Infarction
  • Recurrent Stroke
  • Stroke (CVA) or Transient Ischemic Attack
  • Stroke Recurrence
  • TIA (Transient Ischemic Attack)
  • Vascular Death

Eligibility Criteria

Sex
ALL
Age
40 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cilostazol 100 mg — DRUG
    Cilostazol 100 mg tablet taken orally twice daily following an initial 2-week period during which cilostazol is dosed at 100 mg tablet taken orally once daily to maximize tolerability.
  • Placebo — DRUG
    Placebo 100 mg tablet twice taken orally daily following an initial 2-week period during which placebo is dosed at 100 mg taken orally once daily to maximize tolerability.

Study Details

The goal of this clinical trial is to learn whether adding cilostazol to aspirin or clopidogrel prevents stroke and heart attack in people who have had a stroke or mini-stroke.

Key Dates

Start date
Aug 31, 2026
Status verified
Sep 2025
Primary completion
Jul 31, 2031
Completion
Jul 31, 2031

Study Design

Enrollment
2,000 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: Cilostazol 100mg
    Participants take oral cilostazol until a study endpoint occurs, they reach maximum follow up duration (4 years), the participant withdraws, or the study ends.
  • Placebo Comparator: Placebo
    Participants take oral placebo until a study endpoint occurs, they reach maximum follow up duration (4 years), the participant withdraws, or the study ends.

Primary Outcome Measure

Major adverse cardiovascular event (MACE) [ Time Frame: Up to 4 years after randomization ]

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford UniversityStanfordCalifornia94305-

Find similar trials in Stanford, CA

By condition
Stroke
By specialty
NeurologyBrain disorders
By research site
Stanford University· Stanford, CA

Related Studies